Company Information
Industry 制造业
Company Introduction 浙江医药股份有限公司是一家主营医药生产及销售的公司,主要产品包括了片剂、胶囊剂、口服液、注射剂、原料药等.该公司是我国重要的原料药和制剂生产企业,已成为国家维生素、抗耐药菌抗生素、喹诺酮产品重要的生产基地.公司主导产品维生素E年产量居全国首位,在世界也排名第三.在来立信系列中,公司是国内左氧氟沙星"三强"之一.公司的新型辅酶类添加剂FED产销量居全球第三,是国内唯一一家使用发酵法生产的企业.此外,公司还是我国目前唯一生产苯芴醇的厂家,行业垄断地位十分突出.公司下属新昌制药厂已被中国饲料工程技术研究中心列为国家生物素生产基地,维生素H、吉他霉素产销量居全球第三。
Main Business 化学原料药及其制剂产品的研制、开发、生产与销售。
Legal Representative 李春波
Top Executives
董事长:李春波
副董事长:刘中,吕春雷
董事:苍宏宇,刘中,储振华,俞育庆
独立董事:夏青,吴晓明,裘益政,陈乃蔚
Top 5 Shareholder
Shareholder name Nature Holding Date
新昌县昌欣投资发展有限公司流通A股21.57%31/03/2024
国投高科技投资有限公司流通A股15.66%31/03/2024
香港中央结算有限公司流通A股1.81%31/03/2024
仙居县产业投资发展集团有限公司流通A股1.79%31/03/2024
陈朝晖流通A股1.37%31/03/2024
Company Secretary 邵旻之
Solicitors 国浩律师(上海)事务所
Auditors 天健会计师事务所(特殊普通合伙)
Tel No 0575-85211969
Fax No 0575-85211976
Website www.zmc.top
Email board@zmc-china.com
Company Address
Register: 浙江绍兴滨海新城致远中大道168号
Office: 浙江绍兴滨海新城致远中大道168号
Listing Date 21/10/1999
Shares Capital
Shares Capital: 964,975,000
Total A Share: 964,975,000
Listed A Share: 961,633,475
Non-tradable A Share: 3,341,525
Other Share: 0
Total B Share: 0
Total H Share: 0
EPS(RMB)* ¥ 0.450
DPS(RMB)* ¥ 0.150
NBV Per Share(RMB)* ¥ 9.980
Market Capitalization(RMB) 10.258B
Smiley face Only Chinese content is avaliable
N
/
N
 : Eligible Stock for SH-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SH-HK Ex-Northbound trade (sell only)
N
/
N
 : Eligible Stock for SZ-HK Northbound trade (For all investors/ For institutional professional investors only)
N
 : Eligible Stock for SZ-HK Ex-Northbound trade (sell only)
* Unadjusted Data
Information provided by: etnet
Terms and Conditions
Risk Disclosure:
The prices of securities may fluctuate, sometimes dramatically. The price of a security may move up or down, and may become valueless. It is as likely that losses will be incurred rather than profit made as a result of buying and selling securities. The information is for reference only, it does not constitute any offer, solicitation, recommendation, comment or any guarantee to the purchase or sale of any investment product or service. Customers should not make any investment decisions based on this information alone.
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources, Nanyang Commercial Bank Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.